Finanzen von Anavex Life Sciences Corp (AVXL)AVXLAnavex Life Sciences Corp

Evaluating the bottom line, Anavex Life Sciences Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -12.80%, provide a clear picture of how effectively AVXL converts its operational activities into shareholder value.

In the context of the broader market, AVXL competes directly with industry leaders such as NKTX and ANIX. With a market capitalization of $102.90M, it holds a significant position in the sector. When comparing efficiency, AVXL's gross margin of N/A stands against NKTX's N/A and ANIX's N/A. Such benchmarking helps identify whether Anavex Life Sciences Corp is trading at a premium or discount relative to its financial performance.

Anavex has shown a significant turnaround in net income, reporting a positive net income of 7,824,000 USD in Q3 2026, following several quarters of losses. However, the overall trend remains negative with a year-to-date change of -69.02%.